IDEAYA Closes $345M Public Offering, Underwriters Fully Exercise Option
IDYA sits 35% above its 52-week low of $20.5.
Summary
IDEAYA Biosciences has successfully closed its public offering, securing approximately $345.0 million in gross proceeds. This amount is higher than the initially announced $300 million, reflecting the full exercise of the underwriters' option to purchase additional shares. This significant capital infusion, following recent positive Phase 2/3 clinical trial results for darovasertib and new collaborations, substantially strengthens the company's financial position to advance its precision oncology pipeline.
At the time of this announcement, IDYA was trading at $27.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $20.50 to $39.28. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.